|
1) Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009; 373: 582-92
|
|
|
|
2) Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50: 661-2
|
|
|
|
|
|
3) Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavirin nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009; 49: 1503-14
|
|
|
|
|
|
4) Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003; 10: 298-305
|
|
|
|
|
|
5) Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med. 2005; 142: 240-50
|
|
|
|
|
|
6) Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004; 351: 1206-17
|
|
|
|
|
|
7) Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005; 352: 2682-95
|
|
|
|
|
|
8) Sonneveld MJ, Janssen HL. Chronic hepatitis B: peginterferon or nucleos(t)ide analogues？ Liver Int. 2011; 31 Suppl 1: 78-84
|
|
|
|
|
|
9) Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008; 359: 2442-55
|
|
|
|
|
|
10) Heathcote EJ, Marcellin P, Buti M. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011; 140: 132-43
|
|
|
|
|
|
11) Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology. 2011; 53: 2121-9
|
|
|
|
|
|
12) European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases, 08 June 2009. J Hepatol. 2009; 51: 237-67
|
|
|
|
|
|
13) Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther. 2010; 15: 133-43
|
|
|
|
|
|
14) Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol. 2010; 52: 508-13
|
|
|
|
|
|
15) Chan HL, Wong VW, Wong GL, et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology. 2010; 52: 1232-41
|
|
|
|
|
|
16) Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol. 2010; 52: 514-22
|
|
|
|
|
|
17) Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology. 2010; 139: 483-90
|
|
|
|
|
|
18) Martinot-Peignoux M, Lada O, Cardoso A-C, et al. Quantitative HBsAg: a new specific marker for the diagnosis of HBsAg inactive carriage [Abstract]. Hepatology. 2010; 52: 992A
|
|
|
|
|
|
19) Janssen HL, Kerhof-Los CJ, Heijtink RA, et al. Measurement of HBsAg to monitor hepatitis B viral replication in patients on alphainterferon therapy. Antiviral Res. 1994; 23: 251-7
|
|
|
|
|
|
20) Manesis EK, Schina M, Le Gal F, et al. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. Antivir Ther. 2007; 12: 381-8
|
|
|
|
|
|
21) Manesis EK, Hadziyannis ES, Angelopoulou OP. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther. 2007; 12: 73-82
|
|
|
|
|
|
22) Wiegand J, Wedemeyer H, Finger A, et al. A decline in hepatitis B virus surface antigen (HBsAg) predicts clearance, but does not correlate with quantitative HBeAg or HBVDNA levels. Antivir Ther. 2008; 13: 547-54
|
|
|
|
|
|
23) Lau GK, Marcellin P, Brunetto M, et al. On-treatment HBsAg decline during peginterferon alfa-2a(40kD) 6 lamivudine in patients with HBsAg-positive CHB as a potential predictor of durable off-treatment response [Abstract]. Hepatology. 2008; 48(Suppl): 714A
|
|
|
|
|
|
24) Sonneveld MJ, Rijckborst V, Boucher CA. Prediction of sustained response to peginterferon alfa-2b for hepatitis Be antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology. 2010; 52: 1251-7
|
|
|
|
|
|
25) Marcellin P, Avila C, Wursthorn K, et al. Telbivudine (LdT) plus peg-interferon (pegIFN) in HBeAg positive chronic hepatitis B-very potent antiviral efficacy but risk of peripheral neuropathy (PN). J Hepatol. 2010; 52(Suppl 1): S6-S7
|
|
|
|
|
|
26) Jung YK, Kim JH, Lee YS, et al. Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naïve, hepatitis B e antigen-positive patients receiving entecavir. J Clin Gastroenterol. 2010; 44: 653-7
|
|
|
|
|
|
27) Reijnders JGP, Rijckborst V, Sonneveld MJ, et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol. 2011; 54: 449-54
|
|
|
|
|
|
28) Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology. 2010; 52: 1611-20
|
|
|
|
|
|
29) Gane E, Heathcote EJ, Marcellin P, et al. HBsAg kinetics of decay and baseline characteristics of HBsAg-positive patients with chronic hepatitis B following 3 years of tenofovir disoproxil fumarate (TDF) treatment. J Hepatol. 2010; 52(Suppl 1): S388
|
|
|
|
|
|
30) Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology. 2009; 49: 1141-50
|
|
|
|
|
|
31) Marcellin P, Piratvisuth T, Brunetto, et al. On-treatment decline in serum HBsAg levels predicts sustainedimmune control 1 year post-treatment and subsequent HBsAg clearance in HBsAg-negative hepatitis B virus-infected patients treated with peginterferon alfa [40kD] (PEGASYS). Hepatol Int. 2010; 4: 151
|
|
|
|
|
|
32) Chan HL, Wong VW, Chim AM, et al. Serum HBs-Ag quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther. 2010; 32: 1323-31
|
|
|
|
|
|
33) Piratvisuth T, Lau GKK, Marcelliin P. On-treatment decline in serum HBsAg levels predicts sustained immune control and HBsAg clearance 6 month posttreatment in HBsAg-positive hepatitis B virus-infected patients treated with peginterferon alfa-2a [40kD] (PEGASYS). Hepatol Int. 2010; 4: 152
|
|
|
|
|
|
34) Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg negative patients. Hepatology. 2009; 49: 1151-7
|
|
|
|
|
|
35) Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology. 2010; 52: 454-61
|
|
|
|
|